Study to Enroll 80 Patients Unlikely to Benefit from Venetoclax/Azacitide (Aza/Ven) Therapy in the US and Europe -- SELLAS’ Predictive ...

Now, Chinese scientists have developed a kind of "double-sided tape" that helps the body's own soldiers — engineered immune cells — hold onto cancer cells more tightly, making treatment far more ...

SAN FRANCISCO--(BUSINESS WIRE)--Ossium Health, a clinical-stage bioengineering company that built a first-of-its-kind organ donor-derived bone marrow bank to deploy hematopoietic stem cells for blood ...

CLL is the most common type of leukemia in adults. 3 An estimated 18,500 people were treated for CLL in the 1st-line setting in the US in 2024. 4 Jennifer Brown, MD, PhD, Director of the CLL Center of ...

Frontline patient outcomes are making the case for mipletamig to enhance standard-of-care therapy alongside venetoclax + azacitidine SEATTLE, WA / ACCESS Newswire / March 10, 2026 / Aptevo ...

In "Beyond Diagnosis: CLL," Cleveland Clinic hematologist/oncologist Allison Winter, MD, and host John Mangels explore how clinicians can communicate effectively and ...

Key Takeaways A highly sensitive DNA test can detect hidden leukemia cells that predict if a patient’s cancer is likely to ...

A new CRISPR-based tool that is directly used on patients' cancer cells can identify genes and regulatory elements driving ...

AstraZeneca’s CALQUENCE® (acalabrutinib) in combination with venetoclax has been approved in the US as the first all-oral, fixed-duration regimen for the treatment of adult patients with chronic ...